Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


News & Press Releases

Here you will find the most recent organizational news from FARA, including information on events, and awareness and advocacy initiatives. To locate an article from a certain date, please use the archives on the right side of your screen.

New ICD-10-CM Diagnosis Code G11.11 for Friedreich’s Ataxia Effective October 1, 2020

A new diagnosis code has been approved for Friedreich’s ataxia by the Centers of Medicare and Medicaid Services (CMS), effective October 1, 2020. The new code, ICD-10-CM G11.11, is to be used by clinicians to document the Friedreich’s Ataxia (FA) diagnosis in medical records and is used by health insurance companies to determine coverage approval for claims.

The International Classification of Diseases (ICD) coding system was established by the World Health Organization; currently used by ~100 countries for reporting cause of death and other epidemiology statistics. The system contains codes for diseases, symptoms, abnormal findings, social circumstances, and external causes of injury. ICD-10-CM codes, or diagnosis codes, are used by clinicians to document the need for healthcare services.

When the U.S. converted from ICD-9 to ICD-10 in 2015, the code for FA became less specific because it covered a group of conditions described as “early-onset cerebellar ataxias”. The Friedreich’s Ataxia Research Alliance (FARA), along with physicians in the Collaborative Clinical Research Network in FA, recognized a need for greater specificity and initiated the request for an FA specific code.

FARA Chief Executive Officer, Jennifer Farmer said, “We believe the new FA specific ICD-10 code G11.11 will lead to fewer rejected health insurance claims, help monitor outcomes of clinical management guidelines, and enhance ability to evaluate symptom progression and track disease prevalence.”

Fact sheets regarding use of the new ICD-10 code G11.11 are available for patients and clinicians at


Global, multi-stakeholder, consortium launched to study neuroimaging biomarkers for Friedreich Ataxia


A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA)

Downingtown, PA (September 24, 2020) - The Friedreich’s Ataxia Research Alliance (FARA) and partner organizations proudly announce an international consortium of academic, industry, and patient advocacy partners to launch a natural history study to TRACK brain and spinal cord changes in individuals with Friedreich’s ataxia (FA). Friedreich’s ataxia is a rare debilitating, life-shortening, degenerative neuro-muscular disorder. About 5,000 people in the United States and 15,000 worldwide live with FA.

Read More Here


rideATAXIA Global Challenge

What is the rideATAXIA Global Challenge?

We invited some friends from around the world to help us explain in this video.

To Join Us:

Register Today

Award for Innovative Mindset

FARA, the CureFA Foundation, and fara Australia are proud to announce the recipients of the Award for Innovative Mindset (AIM). AIM was designed to promote the exploration of high-risk, high-gain, and potentially groundbreaking concepts in FA research. The request for proposals was initiated in May, during Friedreich's Ataxia Awareness Month, and the research awards are supported in part by funds raised in the Lend Us Some Muscle campaign. The intent of the award was to inspire creativity, thoughtful reflection, innovation and to advance FA research, during a time when many investigators were away from their labs and daily routines due to the shutdown. Seventeen applications were received and four were awarded funding. A description of each project follows below.

Sanjay Bidichandani
Sanjay Bidichandani, PhD - University of Oklahoma
Single Cell Gene Expression Analysis in Friedreich Ataxia This application proposes a new model to explain the (apparently) high residual level of frataxin seen in FA patients. The current understanding is that FA develops when cells express levels of frataxin protein that are 10‐20% of normal levels. Thus, when compared to other loss-of-function conditions, where disease is typically triggered at residual protein levels/activity of <5%, FA seems to manifest at relatively higher residual protein levels. The hypothesis put forward in this grant proposal is that most FA cells actually express very low levels of frataxin (<5%, as in other recessive disorders), and that a substantial minority of cells show “escape from gene silencing” and thus express near normal levels of transcript due to FXN genes that, despite containing an expanded GAA repeat, are not fully silenced. This group plans to test this hypothesis by analyzing FXN expression and silencing in individual cells. This model has important implications for the understanding of FA pathogenesis, and for the development of treatments.
Cosponsor: CureFA Foundation and fara Australia

Christina Cortez-Jugo
Christina Cortez-Jugo, PhD - University of Melbourne, Australia
Targeted Delivery of Frataxin DNA to Proprioceptors of the Dorsal Root Ganglia
This application proposes to use nanoparticles instead of viruses to deliver the frataxin gene in gene therapy approaches. Nanoparticles are small aggregates made of polymers, lipids and other molecules that can deliver a specific cargo (in this case the frataxin gene) to cells. This investigator proposes to improve the delivery of the cargo to the specific cell types that are mostly affected in FA, by coating the nanoparticle surface with antibodies and ligands that will promote their binding and uptake by the target cells. The ability to target specific cells affected in FA could increase the concentration of the therapeutic where it is needed, and reduce dosage, cost of treatment and side effects.
Cosponsor: CureFA Foundation and fara Australia

Giovanni Manfredi Helene Puccio

Giovanni Manfredi, MD, PhD - Weill Cornell Medicine & Helene Puccio, PhD - Institute NeuroMyoGène, Lyon, France
Mitochondrial integrated stress response in FA cardiomyopathy
The hypothesis of this proposal stems from the observation that death from cardiomyopathy in FA occurs in the third or fourth decade of life, but surprisingly the FA heart often maintains adequate function until shortly before death. This suggests that the FA heart is able to adapt, at least initially, to the defects caused by the loss of frataxin. This adaptation likely involves metabolic rewiring to allow the utilization of alternative energy sources and other events. The investigators propose that these events recapitulate the “mitochondrial integrated stress response” (well characterized in other mitochondrial diseases) which is an evolutionarily conserved response designed to help the organisms face periods of acute stress, but if chronic and unresolved, becomes “maladaptive”. This proposal aims to determine whether there is evidence of mitochondrial integrated stress response in the heart of an FA mouse model.
Cosponsor: CureFA Foundation and fara Australia

Seth Masters
Seth Masters, PhD - Walter and Eliza Hall Institute, Melbourne Australia
Targeting neuroinflammation in Friedreich's Ataxia
This grant proposal addresses the role of inflammation in FA. There is evidence of inflammation due to low levels of frataxin in cell lines, in mouse models, and in patients with FA, however mechanistic insights into the trigger for inflammation in FA are missing. This investigator hypothesizes that a specific innate immune pathway drives inflammation in FA. The cellular pathway normally detects virus/bacteria, but is also known to respond to damaged mitochondria. In FA, the damage to mitochondria due to frataxin loss would cause activation of this specific innate immune pathway. The aim of this proposal is to demonstrate mitochondrial damage leading to activation of this innate immune pathway with associated inflammatory biomarkers which may help stratify and direct therapy for FA.
Cosponsor: CureFA Foundation and fara Australia


Monthly Update - August 2020

Dear friends,

As you know, Fall is the season for many FARA fundraising events, a scientific conference, and our largest educational FA Patient Symposium. We've been working on adapting those events to a virtual format, and we are excited to deliver all of their energy and information straight to your home. You will find the details for these events throughout this newsletter.

We also recently launched a new program called The Pathway - a monthly recurring gift program. In honor of the 1 in 50,000 people living with FA, we set a goal to enroll 50 new contributors in The Pathway over the next couple of weeks. A monthly donation of $10 or more is a budget friendly way to support ongoing research.

In the first week, 20 new participants enrolled in the program, and I am grateful for the opportunity to be one of them. I believe in the power of research to transform lives. FARA funds research along the entire continuum- from the lab bench to the clinical bedside. Sustaining contributions received through The Pathway allow FARA to ensure that researchers are exploring all molecular, systemic and clinical pathways that will lead to treatments and a cure with urgency. ...

Read the Full Monthly Update

Page 11 of 98



News & Press Archives

Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator